
Study findings confirm the benefits of BRAF and MEK inhibitors in mutated non-small cell lung cancer
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients
Final analysis of the KEYNOTE-811 trial reports positive findings when adding pembrolizumab to trastuzumab and chemotherapy in treatment-naïve patients
New positive findings from research in advanced or metastatic breast cancer support the use of these agents in wider patient populations
The fields of metastatic pancreatic NETs and advanced and low proliferative grade 3 disease tumours move forward
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
Subgroup analyses from the ADRIATIC study support previous practice-changing findings
Using treatments only where clear benefit has been demonstrated and modulating doses based on evidence are potentially effective strategies to reduce the rising costs of oncology
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
For recipient of the ESMO Lifetime Achievement Award, Prof. John Haanen, melanoma research has provided him with a career full of innovation, but there is always more to explore
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.